Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride hemihydrate, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of:,? major depression and for the prevention of relapse of depressive symptoms;,? obsessive compulsive disorder and for the prevention of relapse of ocd;,? panic disorder and for the prevention of relapse of panic disorder;,? social anxiety disorder/social phobia; and,? generalised anxiety disorder;,? posttraumatic stress disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paroxetine hydrochloride, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; lactose; hyprolose; hypromellose; macrogol 8000; titanium dioxide - paroxetine is indicated for the treatment of major depression and is effective in preventing the relapse of depressive symptoms. paroxetine is also indicated for the treatment of obsessive compulsive disorder and is effective in preventing the relapse of ocd. paroxetine is also indicated for the treatment of panic disorder and for the prevention of relapse of panic disorder. paroxetine is also indicated for the treatment of social anxiety disorder/social phobia. paroxetine is also indicated for the treatment of generalised anxiety disorder. paroxetine is also indicated for the treatment of posttraumatic stress disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - paroxetine hydrochloride hemihydrate, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate type a; calcium hydrogen phosphate dihydrate; calcium hydrogen phosphate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of:,? major depression and for the prevention of relapse of depressive symptoms;,? obsessive compulsive disorder and for the prevention of relapse of ocd;,? panic disorder and for the prevention of relapse of panic disorder;,? social anxiety disorder/social phobia; and,? generalised anxiety disorder;,? posttraumatic stress disorder.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - paroxetine hydrochloride 22.8mg equivalent to 20 mg paroxetine;   - film coated tablet - 20 mg - active: paroxetine hydrochloride 22.8mg equivalent to 20 mg paroxetine   excipient: calcium hydrogen phosphate dihydrate magnesium stearate opadry white ys-1-7003 sodium starch glycolate - aropax is indicated for the treatment of major depressive disorder (mdd). aropax is indicated for the prevention of relapse and also recurrence of further depressive episodes.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - thioridazine hydrochloride - coated tablets - 10 mg milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - thioridazine hydrochloride - coated tablets - 25 mg milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - thioridazine hydrochloride - coated tablets - 50 mg milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - thioridazine hydrochloride - coated tablets - 100 mg milligram